FolioLanternBeta
JNJJohnson & Johnson · Insider ownership research

Johnson & Johnson insiders sold $155M in the past 12 months. How much of their stake is that?

About 8.8% overall. As a group they ended with more shares than they started with. These figures leave out Joaquin Duato, the largest holder (most of their shares vested during the period, so a percentage would mislead).

Updated Oct 9, 2026 from SEC filings · covers Oct 10, 2025 to Oct 9, 2026
How this comparesMore of their stake sold than at 274 of the 416 other companies we can measure (#143 of 417)See ranking
1
buyer among officers and directors (1 trade), past 12 months
0%
of sales were under disclosed trading plans, past 12 months
10 of 23
officers and directors sold shares, past 12 months
Recent activity · past 30 days, Sep 10, 2026 to Oct 9, 2026

No officer or director trades were reported for the past 30 days. The most recent before that:

Sep 2, 2026Timothy Schmid sold 34K shares ($9.2M) with no plan disclosed. 34K shares came in from vesting or option exercises the same day, so the holding rose by 0 net.
WhoSharesPrice% of total stakeTotal stake afterTrade dateFiled
Timothy Schmid
EVP, WW Chair, MedTech
33,597$274.74n/an/aSep 2, 2026Sep 4, 2026

"% of total stake" is the shares in this event against all the vested shares the person held that day, across every share class and holding entity, after that day's vesting. "n/a" means the person's holdings don't reconcile, or the row is a purchase. "Holdings record incomplete" means more shares were sold than the filings show the person held that day, so a percentage would be wrong.

Is this normal? More than usual: about 3x the 5-year average. 10 insiders sold; the average is 5 a year. Year by year
Latest filing: Filed Sep 4 for a sale on Sep 2. Timothy Schmid sold 34K shares ($9.2M) with no plan disclosed. Filing
63 SEC ownership filings in the period · See the evidence

What stands out

Ten officers sold $155M with no disclosed plan: Joaquin Duato ($66.8M), Joseph Wolk ($21.8M) and John Reed ($17.3M), plus 7 more. The filings don't state a reason.Joaquin Duato: largest such sale, Aug 13, 2026 · Joseph Wolk: largest such sale, Feb 17, 2026 · John Reed: largest such sale, Feb 17, 2026
John Morikis bought 1.2K shares for $258K, first on Nov 26, 2025.Purchase, Nov 26, 2025
Two officers sold shares but ended with larger stakes, because more shares came in than were sold: Jennifer Taubert (sold 15K, 8.4% of starting holdings; 47K added) and Robert Decker (sold 4.1K, 19% of starting holdings; 7.8K added).Jennifer Taubert: largest sale, Aug 17, 2026 · Robert Decker: largest sale, Feb 27, 2026

Percentages cover 7 of 23 officers and directors. 16 are left out

i
Left out: Joaquin Duato, Kathryn Wengel, Joseph Wolk, Vanessa Broadhurst, James Swanson, Elizabeth Forminard and John Reed (most of their shares vested during the period, so a percentage would mislead); Timothy Schmid (holdings couldn't be fully reconciled); Mark McClellan, Mary Beckerle, Jennifer Doudna, Nadja West and Daniel Pinto (held no vested shares at the start); Marillyn Hewson and Hubert Joly (most holdings were last confirmed in 2019); Paula Johnson (most holdings were last confirmed in 2023).
Disclosed company stock is not an insider's whole wealth.

Who sold, and how much of their stake

Officers and directors, past 12 months. Each bar is 100% of that person's own stake; not comparable between people. The stake is the vested shares held at the start of the period (Oct 9, 2025); the gold part is what they sold.

Joaquin Duato
CEO and Chairman of the Board, Director
Sold $66.8M (plan status beside the amount). That is 47% of the shares held or received (after tax withholding) during the period†. A share of the starting stake is not shown: most of these shares arrived during the period. Why
$66.8MNo plan disclosed
Joseph Wolk
Exec VP, CFO
Sold $21.8M (plan status beside the amount). That is 51% of the shares held or received (after tax withholding) during the period†. A share of the starting stake is not shown: most of these shares arrived during the period. Why
$21.8MNo plan disclosed
John Reed
EVP, Innovative Medicine, R&D
Sold $17.3M (plan status beside the amount). That is 75% of the shares held or received (after tax withholding) during the period†. A share of the starting stake is not shown: most of these shares arrived during the period. Why
$17.3MNo plan disclosed
James Swanson
EVP, CIO
Sold $15.1M (plan status beside the amount). That is 71% of the shares held or received (after tax withholding) during the period†. A share of the starting stake is not shown: most of these shares arrived during the period. Why
$15.1MNo plan disclosed
Timothy Schmid
EVP, WW Chair, MedTech
Sold $15.1M (plan status beside the amount). Share of stake not shown: holdings couldn't be fully reconciled. Why
$15.1MNo plan disclosed
All 10 sellers

Selling by month

Officers and directors, Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.

No plan disclosedOne dollar scale for every month; the tallest bar is labeled
Oct 2025: $4.2M no plan disclosedOctNovDecJan 2026: $22.1M no plan disclosedJanFeb 2026: $58.4M no plan disclosed$58.4MFebMarAprMayJun 2026: $2.4M no plan disclosedJunJul 2026: $5.8M no plan disclosedJulAug 2026: $52.8M no plan disclosedAugSep 2026: $9.2M no plan disclosedSepOct

Common questions

Is the Johnson & Johnson CEO selling stock?

Yes. Joaquin Duato sold 272K shares ($66.8M) in the past 12 months, none of it under a trading plan disclosed in the filings.

Why are Johnson & Johnson insiders selling?

Filings rarely give a reason, and we don't guess at one. What they show is how the sales were made: 0% of sales by value ran under 10b5-1 trading plans disclosed in the filings and 100% had no disclosed plan. A trading plan schedules sales in advance.

Are any Johnson & Johnson insiders buying?

Yes. 1 officer or director reported 1 purchase in the past 12 months (Form 4 code P, which includes private purchases).

How much of their stake did Johnson & Johnson insiders sell?

About 8.8% overall. As a group they ended with more shares than they started with. These figures leave out Joaquin Duato, the largest holder (most of their shares vested during the period, so a percentage would mislead). That covers the 12 months to Oct 9, 2026 and counts vested shares reported on SEC Forms 3, 4 and 5, which is not an insider's whole wealth.

The evidence

Who sold10 officers and directors: amount, % of holdings, trading plan
Who soldAmount% of holdingsTrading plan
Joaquin Duato
CEO and Chairman of the Board, Director
$66.8M
272K shares
47%†
i
† Most of the shares Joaquin Duato sold arrived during the period, so this is shares sold as a share of the 408K held at the start plus the 208K received, less 36K withheld by the company for taxes.
No plan disclosed
Joseph Wolk
Exec VP, CFO
$21.8M
90K shares
51%†
i
† Most of the shares Joseph Wolk sold arrived during the period, so this is shares sold as a share of the 85K held at the start plus the 108K received, less 18K withheld by the company for taxes.
No plan disclosed
John Reed
EVP, Innovative Medicine, R&D
$17.3M
76K shares
75%†
i
† Most of the shares John Reed sold arrived during the period, so this is shares sold as a share of the 11K held at the start plus the 102K received, less 12K withheld by the company for taxes.
No plan disclosed
James Swanson
EVP, CIO
$15.1M
62K shares
71%†
i
† Most of the shares James Swanson sold arrived during the period, so this is shares sold as a share of the 19K held at the start plus the 73K received, less 4.2K withheld by the company for taxes.
No plan disclosed
Timothy Schmid
EVP, WW Chair, MedTech
$15.1M
58K shares
i
No percentage: holdings couldn't be fully reconciled.
No plan disclosed
Vanessa Broadhurst
EVP, Global Corp Affairs
$7.3M
29K shares
56%†
i
† Most of the shares Vanessa Broadhurst sold arrived during the period, so this is shares sold as a share of the 24K held at the start plus the 33K received, less 4.4K withheld by the company for taxes.
No plan disclosed
Elizabeth Forminard
EVP, Chief Legal Officer
$4.1M
16K shares
48%†
i
† Most of the shares Elizabeth Forminard sold arrived during the period, so this is shares sold as a share of the 13K held at the start plus the 35K received, less 15K withheld by the company for taxes.
No plan disclosed
Jennifer Taubert
EVP, WWC. Innovative Medicine
$4.0M
15K shares
8.4%No plan disclosed
Kathryn Wengel
EVP, Chief TO and Risk Officer
$2.4M
10K shares
8%†
i
† Most of the shares Kathryn Wengel sold arrived during the period, so this is shares sold as a share of the 95K held at the start plus the 65K received, less 35K withheld by the company for taxes.
No plan disclosed
Robert Decker
VP Corporate Controller
$1.0M
4.1K shares
19%No plan disclosed
The full ownership picture22 of 23 insiders fully reconciled · 15 officers and directors

Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.

InsiderHeld Oct 9, 2025SoldHeld Oct 9, 2026Still held
Joaquin Duato
i
Minor difference of 44 shares. Difference is under 0.5% of holdings.
CEO and Chairman of the Board, Director
408K−272K308Knot meaningful
Vesting, gifts, unvested awards and holding lines for Joaquin Duato
+208Kshares vested or exercised
0gifted (net of own trusts)
−36Kwithheld by the company for taxes
24K → 22Kunvested awards, start → end
Held throughShare classOct 9, 2025Oct 9, 2026
DirectCommon Stock275,967275,967
SpouseCommon Stock130,85230,852
401kCommon Stock9741,018

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
177,816$157.92Feb 15, 2034$20.8M
219,020$156.15Feb 15, 2035$26.0M
131,734$243.45Feb 15, 2036$4.1M

Estimate: options held × ($274.74 − strike price), using the most recent insider trade price on Form 4 (Sep 2, 2026), not a market close.

Reconciliation: minor difference of 44 shares. Difference is under 0.5% of holdings.

Jennifer Taubert
EVP, WWC. Innovative Medicine
178K−15K194K+9.2%
Vesting, gifts, unvested awards and holding lines for Jennifer Taubert
+47Kshares vested or exercised
0gifted (net of own trusts)
−16Kwithheld by the company for taxes
10K → 9.2Kunvested awards, start → end
Held throughShare classOct 9, 2025Oct 9, 2026
DirectCommon Stock178,013194,451

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
28,712$115.67Feb 13, 2027$4.6M
76,981$157.92Feb 15, 2034$9.0M
89,781$156.15Feb 15, 2035$10.6M
54,869$243.45Feb 15, 2036$1.7M

Estimate: options held × ($274.74 − strike price), using the most recent insider trade price on Form 4 (Sep 2, 2026), not a market close.

Kathryn Wengel
i
Minor difference of 15 shares. Difference is under 0.5% of holdings.
EVP, Chief TO and Risk Officer
95K−10K115Knot meaningful
Vesting, gifts, unvested awards and holding lines for Kathryn Wengel
+65Kshares vested or exercised
0gifted (net of own trusts)
−35Kwithheld by the company for taxes
3.8K → 3.1Kunvested awards, start → end
Held throughShare classOct 9, 2025Oct 9, 2026
DirectCommon Stock94,281114,288
ESOPCommon Stock281281
401kCommon Stock7590

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
32,965$115.67Feb 13, 2027$5.2M
29,275$157.92Feb 15, 2034$3.4M
30,841$156.15Feb 15, 2035$3.7M
16,945$243.45Feb 15, 2036$530K

Estimate: options held × ($274.74 − strike price), using the most recent insider trade price on Form 4 (Sep 2, 2026), not a market close.

Reconciliation: minor difference of 15 shares. Difference is under 0.5% of holdings.

Joseph Wolk
i
Minor difference of 28 shares. Difference is under 0.5% of holdings.
Exec VP, CFO
85K−90K85Knot meaningful
Vesting, gifts, unvested awards and holding lines for Joseph Wolk
+108Kshares vested or exercised
0gifted (net of own trusts)
−18Kwithheld by the company for taxes
11K → 9.6Kunvested awards, start → end
Held throughShare classOct 9, 2025Oct 9, 2026
DirectCommon Stock14,00014,000
SLATCommon Stock68,83568,835
401kCommon Stock2,1452,173

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
33,000$131.94Feb 12, 2029$4.7M
95,197$157.92Feb 15, 2034$11.1M
91,277$156.15Feb 15, 2035$10.8M
53,793$243.45Feb 15, 2036$1.7M

Estimate: options held × ($274.74 − strike price), using the most recent insider trade price on Form 4 (Sep 2, 2026), not a market close.

Reconciliation: minor difference of 28 shares. Difference is under 0.5% of holdings.

Vanessa Broadhurst
EVP, Global Corp Affairs
24K−29K23Knot meaningful
Vesting, gifts, unvested awards and holding lines for Vanessa Broadhurst
+33Kshares vested or exercised
0gifted (net of own trusts)
−4.4Kwithheld by the company for taxes
3K → 2.6Kunvested awards, start → end
Held throughShare classOct 9, 2025Oct 9, 2026
DirectCommon Stock23,59423,003

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
23,745$157.92Feb 15, 2034$2.8M
25,538$156.15Feb 15, 2035$3.0M
14,405$243.45Feb 15, 2036$451K

Estimate: options held × ($274.74 − strike price), using the most recent insider trade price on Form 4 (Sep 2, 2026), not a market close.

Robert Decker
i
Minor difference of 26 shares. Difference is under 0.5% of holdings.
VP Corporate Controller
22K−4.1K24K+12%
Vesting, gifts, unvested awards and holding lines for Robert Decker
+7.8Kshares vested or exercised
0gifted (net of own trusts)
−1.1Kwithheld by the company for taxes
2K → 1.7Kunvested awards, start → end
Held throughShare classOct 9, 2025Oct 9, 2026
DirectCommon Stock21,00123,682
401kCommon Stock620646
ESOPCommon Stock134134

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
8,175$157.92Feb 15, 2034$955K
8,357$156.15Feb 15, 2035$991K
4,871$243.45Feb 15, 2036$152K

Estimate: options held × ($274.74 − strike price), using the most recent insider trade price on Form 4 (Sep 2, 2026), not a market close.

Reconciliation: minor difference of 26 shares. Difference is under 0.5% of holdings.

James Swanson
i
Minor difference of 2 shares. Difference is under 0.5% of holdings.
EVP, CIO
19K−62K26Knot meaningful
Vesting, gifts, unvested awards and holding lines for James Swanson
+73Kshares vested or exercised
0gifted (net of own trusts)
−4.2Kwithheld by the company for taxes
3.6K → 3.3Kunvested awards, start → end
Held throughShare classOct 9, 2025Oct 9, 2026
DirectCommon Stock18,85025,698

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
23,745$157.92Feb 15, 2034$2.8M
34,476$156.15Feb 15, 2035$4.1M
19,449$243.45Feb 15, 2036$609K

Estimate: options held × ($274.74 − strike price), using the most recent insider trade price on Form 4 (Sep 2, 2026), not a market close.

Reconciliation: minor difference of 2 shares. Difference is under 0.5% of holdings.

Timothy Schmid
!
Holdings couldn't be fully reconciled. Balance changed without a matching transaction, and the footnote does not state the amount: +1,791 shares on Feb 6, 2026 (Direct). See the filing Sales and other transactions for Timothy Schmid are complete.
EVP, WW Chair, MedTech
n/a−58Kn/an/a
Vesting, gifts, unvested awards and holding lines for Timothy Schmid
+79Kshares vested or exercised
0gifted (net of own trusts)
−13Kwithheld by the company for taxes
5.6K → 5.6Kunvested awards, start → end

Holdings couldn't be fully reconciled. Balance changed without a matching transaction, and the footnote does not state the amount: +1,791 shares on Feb 6, 2026 (Direct). The balances below are as reported, not verified totals.

Held throughShare classOct 9, 2025Oct 9, 2026
DirectCommon Stock15,09825,447
401kCommon Stock722758
ESOPCommon Stock4646

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
12,388$162.75Feb 13, 2033$1.4M
21,574$164.62Feb 8, 2031$2.4M
17,431$165.89Feb 14, 2032$1.9M
49,658$157.92Feb 15, 2034$5.8M
49,878$156.15Feb 15, 2035$5.9M
35,489$243.45Feb 15, 2036$1.1M

Estimate: options held × ($274.74 − strike price), using the most recent insider trade price on Form 4 (Sep 2, 2026), not a market close.

Kristen Mulholland
EVP, Chief HR Officer
14K020Kno sales
Vesting, gifts, unvested awards and holding lines for Kristen Mulholland
+11Kshares vested or exercised
0gifted (net of own trusts)
−4.9Kwithheld by the company for taxes
6.1K → 6.1Kunvested awards, start → end
Held throughShare classOct 9, 2025Oct 9, 2026
DirectCommon Stock14,11919,830

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
7,976$115.67Feb 13, 2027$1.3M
9,573$129.51Feb 11, 2028$1.4M
7,063$131.94Feb 11, 2029$1.0M
11,416$151.41Feb 10, 2030$1.4M
8,537$164.62Feb 8, 2031$940K
9,949$165.89Feb 14, 2032$1.1M
10,191$162.75Feb 13, 2033$1.1M
10,108$157.92Feb 15, 2034$1.2M
27,951$156.15Feb 15, 2035$3.3M
20,322$243.45Feb 15, 2036$636K

Estimate: options held × ($274.74 − strike price), using the most recent insider trade price on Form 4 (Sep 2, 2026), not a market close.

Elizabeth Forminard
EVP, Chief Legal Officer
13K−16K17Knot meaningful
Vesting, gifts, unvested awards and holding lines for Elizabeth Forminard
+35Kshares vested or exercised
0gifted (net of own trusts)
−15Kwithheld by the company for taxes
5.8K → 5Kunvested awards, start → end
Held throughShare classOct 9, 2025Oct 9, 2026
DirectCommon Stock12,85316,994

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
46,406$157.92Feb 15, 2034$5.4M
51,688$156.15Feb 15, 2035$6.1M
27,076$243.45Feb 15, 2036$847K

Estimate: options held × ($274.74 − strike price), using the most recent insider trade price on Form 4 (Sep 2, 2026), not a market close.

John Reed
EVP, Innovative Medicine, R&D
11K−76K25Knot meaningful
Vesting, gifts, unvested awards and holding lines for John Reed
+102Kshares vested or exercised
0gifted (net of own trusts)
−12Kwithheld by the company for taxes
33K → 8.6Kunvested awards, start → end
Held throughShare classOct 9, 2025Oct 9, 2026
DirectCommon Stock10,65824,911

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
21,721$157.92Feb 15, 2034$2.5M
59,854$156.15Feb 15, 2035$7.1M
49,382$243.45Feb 15, 2036$1.5M

Estimate: options held × ($274.74 − strike price), using the most recent insider trade price on Form 4 (Sep 2, 2026), not a market close.

Mark Weinberger
Director
1K01Kno sales
Vesting, gifts, unvested awards and holding lines for Mark Weinberger
0shares vested or exercised
0gifted (net of own trusts)
20K → 32Kunvested awards, start → end
Held throughShare classOct 9, 2025Oct 9, 2026
DirectCommon Stock1,0001,000
John Morikis
Director
59901.8Kno sales
Vesting, gifts, unvested awards and holding lines for John Morikis
0shares vested or exercised
0gifted (net of own trusts)
0 → 1.5Kunvested awards, start → end
Held throughShare classOct 9, 2025Oct 9, 2026
DirectCommon Stock5991,849
Thomas Cavanaugh
i
Started reporting during the period; starting holdings are from the Form 3.
EVP WW Chair, Innovative Med.
4990499no sales
Vesting, gifts, unvested awards and holding lines for Thomas Cavanaugh
0shares vested or exercised
0gifted (net of own trusts)
5.3K → 5.3Kunvested awards, start → end
  • Started reporting during the period; starting holdings are from the Form 3.
Held throughShare classOct 9, 2025Oct 9, 2026
DirectCommon Stock7171
401kCommon Stock428428

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
15,839$243.45Feb 15, 2036$496K
25,493$156.15Feb 15, 2035$3.0M
23,311$157.92Feb 15, 2034$2.7M
15,081$162.75Feb 13, 2033$1.7M
11,906$165.89Feb 14, 2032$1.3M
14,383$164.62Feb 8, 2031$1.6M
16,543$151.41Feb 10, 2030$2.0M

Estimate: options held × ($274.74 − strike price), using the most recent insider trade price on Form 4 (Sep 2, 2026), not a market close.

Eugene Woods
Director
1500150no sales
Vesting, gifts, unvested awards and holding lines for Eugene Woods
0shares vested or exercised
0gifted (net of own trusts)
24K → 48Kunvested awards, start → end
Held throughShare classOct 9, 2025Oct 9, 2026
TrustCommon Stock150150

22 of 23 insiders fully reconciled: starting holdings plus reported transactions match ending holdings (17 exactly, 5 with a minor or footnoted difference). For 1 we show sales but not holdings; the ! icon on that row explains why. Percentages cover 7 of 23 officers and directors. Left out: Joaquin Duato, Kathryn Wengel, Joseph Wolk, Vanessa Broadhurst, James Swanson, Elizabeth Forminard and John Reed (most of their shares vested during the period, so a percentage would mislead); Timothy Schmid (holdings couldn't be fully reconciled); Mark McClellan, Mary Beckerle, Jennifer Doudna, Nadja West and Daniel Pinto (held no vested shares at the start); Marillyn Hewson and Hubert Joly (most holdings were last confirmed in 2019); Paula Johnson (most holdings were last confirmed in 2023). "Still held" compares ending with starting vested shares; a plus sign means the holding grew.

What explains the selling$155M of sales by plan status, purpose, seller and month

Officer and director open-market sales: $155M across 630,943 shares. Plan status and stated purpose are separate questions, and a sale can have both.

By plan status

No plan disclosed · $155M

Sales with no 10b5-1 plan and no tax reference in the filing. $66.8M of it is Joaquin Duato. No plan disclosed is a statement about the filing, not about why the sale happened. Largest such sale: Joaquin Duato, Aug 13, 2026

Taxes

158,339 shares ($38.3M) were withheld by the company for taxes, which isn't a market sale.

Purchases · 1 buyer (1 trade)

1 officer or director bought shares in this period, in 1 trade(Form 4 code P). Across all their filings on record there are 5 purchase trades.

SellerShares soldProceedsUnder a disclosed planShare of totalSales dates
Joaquin Duato
CEO and Chairman of the Board, Director
272K$66.8M0%43%Jan 26, 2026 to Aug 13, 2026
Joseph Wolk
Exec VP, CFO
90K$21.8M0%14%Feb 17, 2026 to Feb 17, 2026
John Reed
EVP, Innovative Medicine, R&D
76K$17.3M0%11%Oct 17, 2025 to Feb 17, 2026
James Swanson
EVP, CIO
62K$15.1M0%10%Feb 13, 2026 to Feb 17, 2026
Timothy Schmid
EVP, WW Chair, MedTech
58K$15.1M0%10%Feb 18, 2026 to Sep 2, 2026
Vanessa Broadhurst
EVP, Global Corp Affairs
29K$7.3M0%5%Feb 17, 2026 to Jul 20, 2026
Elizabeth Forminard
EVP, Chief Legal Officer
16K$4.1M0%3%Aug 6, 2026 to Aug 6, 2026
Jennifer Taubert
EVP, WWC. Innovative Medicine
15K$4.0M0%3%Aug 17, 2026 to Aug 17, 2026
Kathryn Wengel
EVP, Chief TO and Risk Officer
10K$2.4M0%2%Jun 11, 2026 to Jun 11, 2026
Robert Decker
VP Corporate Controller
4.1K$1.0M0%0.7%Feb 27, 2026 to Feb 27, 2026

Sales by month

MonthSale proceedsDisclosed planTo cover taxesNo plan disclosed
Oct 2025$4.2M$0$0$4.2M
Nov 2025$0$0$0$0
Dec 2025$0$0$0$0
Jan 2026$22.1M$0$0$22.1M
Feb 2026$58.4M$0$0$58.4M
Mar 2026$0$0$0$0
Apr 2026$0$0$0$0
May 2026$0$0$0$0
Jun 2026$2.4M$0$0$2.4M
Jul 2026$5.8M$0$0$5.8M
Aug 2026$52.8M$0$0$52.8M
Sep 2026$9.2M$0$0$9.2M
Oct 2026$0$0$0$0
Is this normal? Selling year by year5 earlier years to compare with

More than usual: about 3x the 5-year average. 10 insiders sold; the average is 5 a year.

12 months endingShares soldInsiders who soldProceeds
Oct 9, 2026
Latest 12 months
631K10$155M
Oct 9, 2025
1 year earlier
239K6$41.9M
Oct 9, 2024
2 years earlier
74K3$11.7M
Oct 10, 2023
3 years earlier
445K9$76.6M
Oct 10, 2022
4 years earlier
123K4$21.7M
Oct 10, 2021
5 years earlier
55K1$8.4M

Open-market sales (Form 4 code S) by people who were officers or directors, in split-adjusted shares. Earlier years include people who have since left. A sale that an outside holder also reports (a family trust, a fund) is counted with outside holders in every year. Shares, not dollars, are compared, so a change in the stock price doesn't look like a change in selling. Years the filings don't fully cover are shown but left out of the average.

Known gaps and uncertainty1 insider whose holdings couldn't be fully reconciled

Timothy Schmid: holdings couldn't be fully reconciled (difference of 1,827 shares). Balance changed without a matching transaction, and the footnote does not state the amount: +1,791 shares on Feb 6, 2026 (Direct). Filing, Feb 6, 2026

Footnote: "Reflects the auto-exercise of options immediately prior to their expiration."

Joaquin Duato: minor difference of 44 shares. Difference is under 0.5% of holdings.

Kathryn Wengel: minor difference of 15 shares. Difference is under 0.5% of holdings.

Joseph Wolk: minor difference of 28 shares. Difference is under 0.5% of holdings.

Robert Decker: minor difference of 26 shares. Difference is under 0.5% of holdings.

James Swanson: minor difference of 2 shares. Difference is under 0.5% of holdings.

Inferred rename: "401 (k) and ESOP Savings Plan" is treated as the same holder as "401 (k) and ESOP Savings Plans", because the old name was never reported again and the new one opened with the same balance (8,432 shares). Old name, new name

Inferred rename: "In Trust for Son" is treated as the same holder as "In Trust for Daughter", because the old name was never reported again and the new one opened with the same balance (19,600 shares). Old name, new name

Inferred rename: "Son" is treated as the same holder as "Daughter", because the old name was never reported again and the new one opened with the same balance (800 shares). Old name, new name

Inferred rename: "Johnson & Johnson Stock Fund under the 401(k) Savings Plan" is treated as the same holder as "Johnson & Johnson Stock Fund in the 401(k) Plan", because the old name was never reported again and the new one opened with the same balance (422 shares). Old name, new name

Inferred rename: "ESOP under the 401(k) Savings Plan" is treated as the same holder as "ESOP in the 401(k) Plan", because the old name was never reported again and the new one opened with the same balance (1,594 shares). Old name, new name

Inferred rename: "ESOP in the 401(k) Plan" is treated as the same holder as "ESOP", because the old name was never reported again and the new one opened with the same balance (1,594 shares). Old name, new name

Inferred rename: "Johnson & Johnson Stock Fund in the 401(k) Savings Plan" is treated as the same holder as "Johnson & Johnson Stock Fund in the 401(k) plan", because the old name was never reported again and the new one opened with the same balance (59 shares). Old name, new name

Inferred rename: "ESOP in the 401(k) Savings Plan" is treated as the same holder as "ESOP in the 401(k) plan", because the old name was never reported again and the new one opened with the same balance (225 shares). Old name, new name

Inferred rename: "ESOP in the 401(k) plan" is treated as the same holder as "ESOP", because the old name was never reported again and the new one opened with the same balance (225 shares). Old name, new name

Inferred rename: "In Trust" is treated as the same holder as "Trust", because the old name was never reported again and the new one opened with the same balance (11,500 shares). Old name, new name

Inferred rename: "ESOP under the 401(k) Savings Plan" is treated as the same holder as "ESOP", because the old name was never reported again and the new one opened with the same balance (1,074 shares). Old name, new name

Inferred rename: "Johnson & Johnson Stock Fund under the 401(k) Savings Plan" is treated as the same holder as "Johnson & Johnson Stock Fund in the 401(k) plan", because the old name was never reported again and the new one opened with the same balance (59 shares). Old name, new name

Inferred rename: "ESOP under the 401(k) Savings Plan" is treated as the same holder as "ESOP in the 401(k) plan", because the old name was never reported again and the new one opened with the same balance (1,287 shares). Old name, new name

Inferred rename: "ESOP in the 401(k) plan" is treated as the same holder as "ESOP", because the old name was never reported again and the new one opened with the same balance (1,287 shares). Old name, new name

Inferred typo: the share class "Commmon" is treated as the same class as "Common" on 1 holding line, because the two spellings are nearly identical and each balance carried over exactly. Example (Russell Deyo, 16,705 shares): old title, new title

External context: we only cite outside events when a documented connection exists. None is shown for this period.

Sources and methodology1,875 filings from SEC EDGAR, and how we read them

All 1,875 Forms 3, 4 and 5 filed for Johnson & Johnson (SEC CIK 200406) from Feb 20, 1997 to Sep 10, 2026, retrieved from SEC EDGAR on Oct 9, 2026. Prices are the ones reported in each filing, often weighted averages. 68 filings were left out because Johnson & Johnson filed them as an owner of another company's stock. 104 older filings exist only on paper and could not be read.

Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.

Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".

Full methodology

Former or inactive filers (54)No filing in 18 months; last reported balances, not in any total
NameLast filedLast reported balance
Scott DavisOct 15, 2024No balance on record
Anne MulcahyApr 29, 20246,537 shares, last reported balance as of Dec 14, 2018
Darius AdamczykApr 29, 20241,063 shares, last reported balance as of Feb 15, 2022
Peter FasoloFeb 20, 2024112,076 shares, last reported balance as of Feb 13, 2024
William HaitFeb 20, 202438,647 shares, last reported balance as of Feb 13, 2024
Ashley McEvoyAug 25, 202355,144 shares, last reported balance as of Aug 23, 2023
Eugene WashingtonMar 9, 20232,766 shares, last reported balance as of Jun 11, 2013
Thibaut MongonFeb 15, 202365,915 shares, last reported balance as of Feb 13, 2023
Alex GorskyJan 18, 2023769,806 shares, last reported balance as of Jan 17, 2023
Charles PrinceFeb 17, 202229,320 shares, last reported balance as of Dec 14, 2018
Ian DavisFeb 17, 20224,193 shares, last reported balance as of Feb 10, 2014
Ronald WilliamsFeb 17, 20223,650 shares, last reported balance as of Jun 10, 2014
Michael UllmannFeb 17, 2022161,954 shares, last reported balance as of Feb 15, 2022
Mathai MammenFeb 17, 202241,934 shares, last reported balance as of Feb 15, 2022
Paulus StoffelsFeb 17, 2021275,547 shares, last reported balance as of Feb 12, 2021
Michael SneedFeb 17, 202166,060 shares, last reported balance as of Feb 12, 2021
William PerezMar 17, 202025,130 shares, last reported balance as of Mar 13, 2020
Ronald KapustaFeb 12, 201918,522 shares, last reported balance as of Feb 11, 2019
Jorge MesquitaFeb 12, 201927,344 shares, last reported balance as of Feb 11, 2019
Dominic CarusoFeb 14, 2018172,530 shares, last reported balance as of Feb 12, 2018
Sandra PetersonFeb 14, 201883,349 shares, last reported balance as of Feb 12, 2018
Gary PrudenMar 2, 201743,726 shares, last reported balance as of Feb 28, 2017
Susan LindquistSep 9, 201616,023 shares, last reported balance as of Feb 9, 2015
Mary ColemanFeb 10, 201611,952 shares, last reported balance as of Nov 12, 2015
Leo MullinFeb 11, 201527,395 shares, last reported balance as of Feb 10, 2014
James CullenFeb 11, 20151,489 shares, last reported balance as of Sep 10, 2014
Stephen CosgroveFeb 11, 2015107,266 shares, last reported balance as of Jan 16, 2015
James CullenFeb 11, 2015No balance on record
Michael JohnsFeb 12, 201415,290 shares, last reported balance as of Feb 10, 2014
David SatcherFeb 13, 201315,393 shares, last reported balance as of Feb 11, 2013
William WeldonFeb 12, 2013388,484 shares, last reported balance as of Feb 8, 2013
Russell DeyoFeb 23, 2012174,422 shares, last reported balance as of Feb 22, 2012
Sherilyn McCoyFeb 13, 201287,927 shares, last reported balance as of Feb 9, 2012
Colleen GogginsJan 12, 2011110,175 shares, last reported balance as of Jan 10, 2011
Arnold LangboMar 11, 20109,684 shares, last reported balance as of Mar 9, 2010
Arnold LangboMar 11, 2010700 shares, last reported balance as of Mar 9, 2010
Kaye Foster-CheekJan 5, 20106,733 shares, last reported balance as of Dec 31, 2009
Nicholas ValerianiOct 2, 200981,255 shares, last reported balance as of Sep 30, 2009
Donald Casey Jr.Sep 14, 200946,375 shares, last reported balance as of Sep 10, 2009
Christine PoonFeb 17, 200956,067 shares, last reported balance as of Feb 13, 2009
Joseph ScodariMay 30, 200821,491 shares, last reported balance as of May 28, 2008
Steven ReinemundMar 12, 20087,567 shares, last reported balance as of Mar 11, 2008
Ann JordanMar 13, 200713,290 shares, last reported balance as of Mar 13, 2007
Robert DarrettaFeb 21, 2007209,056 shares, last reported balance as of Feb 16, 2007
Per PetersonFeb 21, 200732,833 shares, last reported balance as of Feb 16, 2007
Michael DormerOct 26, 200619,377 shares, last reported balance as of Oct 24, 2006
Joann HeisenJan 4, 2006170,040 shares, last reported balance as of Dec 30, 2005
Henry SchachtMay 2, 20053,900 shares, last reported balance as of Apr 28, 2005
Judah FolkmanMay 2, 20053,811 shares, last reported balance as of Apr 28, 2005
Gerard BurrowMay 2, 200510,667 shares, last reported balance as of Apr 28, 2005
Brian PerkinsSep 8, 200463,633 shares, last reported balance as of Sep 3, 2004
Roger FineSep 1, 2004248,612 shares, last reported balance as of Aug 31, 2004
James LenehanJul 1, 2004208,682 shares, last reported balance as of Jun 30, 2004
Robert WilsonAug 21, 20031,102,277 shares, last reported balance as of Aug 19, 2003

Spotted something wrong on this page? Report an error. We check every report against the SEC filing and list what we fix in the corrections log.